ABBVIE (ABBV) Earnings Date & Reports

Key Takeaways

• AbbVie reported third-quarter 2026 worldwide net revenues of $17.404 billion, up 10.3% year over year and slightly above Wall Street's consensus of roughly $17.36 billion.
• Adjusted diluted earnings per share (EPS) came in at $3.82, ahead of the consensus estimate of about $3.74, while GAAP (Generally Accepted Accounting Principles) diluted EPS reached $2.37.
• Immunology led the beat, with Skyrizi sales of about $5.78 billion and Rinvoq sales of about $2.71 billion more than offsetting a 31.2% decline in legacy blockbuster Humira.
• AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $13.95 to $13.99 and announced a 5.2% dividend increase to $1.82 per share.
• Aesthetics remained the main soft spot, while oncology growth stayed subdued as Imbruvica continued to decline.
• For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast pages dedicated to ABBV.
• Discover additional market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

AbbVie's third-quarter 2026 results mark another milestone in the company's long-running transition away from Humira, its former top-selling immunology drug that has faced sustained biosimilar competition. Investors closely watch whether growth engines Skyrizi and Rinvoq can continue scaling fast enough to offset that erosion, and this quarter delivered a clear affirmative. Strong momentum across the immunology and neuroscience franchises, combined with a raised full-year outlook and dividend increase, underscores management's confidence. The results also highlight ongoing challenges in aesthetics and oncology, areas where competitive and economic pressures continue to weigh on performance.

Reported Results

AbbVie posted worldwide net revenues of $17.404 billion for the third quarter ended September 30, 2026, up 10.3% from $15.776 billion a year earlier and modestly above the analyst consensus of about $17.36 billion. GAAP diluted EPS was $2.37, up sharply from $0.10 in the prior-year quarter, while adjusted diluted EPS reached $3.82, roughly double the $1.86 recorded a year ago and ahead of the consensus of approximately $3.74.

By franchise, immunology revenues rose 16.3% to $9.165 billion, led by Skyrizi (about $5.78 billion, up roughly 23%) and Rinvoq (about $2.71 billion, up nearly 24%). Humira fell 31.2% to $683 million. Neuroscience revenue increased 19.4% to $3.389 billion, with Vraylar surpassing $1.07 billion. Oncology edged up 0.8% to $1.696 billion, while aesthetics declined 1.4% to $1.176 billion. Net income attributable to AbbVie jumped to $4.218 billion from $186 million a year ago.

Management raised full-year 2026 adjusted diluted EPS guidance to $13.95 to $13.99, up from the prior $13.76 to $13.96, and lifted full-year revenue guidance by $200 million. The company also declared a quarterly dividend of $1.82 per share, a 5.2% increase.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research workflow.

Market Reaction and Investor Sentiment

Initial market response was mixed. AbbVie's adjusted EPS beat consensus and revenue landed slightly above expectations, but the raised full-year guidance midpoint of roughly $13.97 was essentially in line with Wall Street estimates, leaving limited room for a positive re-rating. Some reports noted shares trading flat to modestly lower in early trading despite the headline beat, while others highlighted a rebound in sentiment driven by the dividend increase and continued immunology strength. The results reinforced the view that AbbVie's post-Humira growth strategy remains intact, though investors remain watchful of lingering softness in aesthetics and oncology.

Forward Outlook and Key Factors to Monitor

Following this quarter, investors should track whether Skyrizi and Rinvoq sustain their double-digit momentum, particularly as new indications such as Rinvoq in vitiligo and alopecia areata progress toward potential U.S. approvals. Management expects these two additions to contribute nearly $2 billion in peak sales, and their commercialization trajectory will be a key catalyst.

The aesthetics business deserves continued attention. Botox Cosmetic returned to modest growth, but Juvéderm declined again amid softer consumer confidence and dermal filler headwinds. Signs of stabilization in the category, along with the rollout of new innovations, could support a gradual recovery.

In oncology, investors should monitor pipeline progress, including potential approvals for etentamig in multiple myeloma and Epkinly in frontline diffuse large B-cell lymphoma (DLBCL), which management flagged as important catalysts for 2027. The completed acquisition of Apogee Therapeutics also adds new immunology and respiratory assets worth watching. Finally, AbbVie's updated guidance, dividend trajectory, and any fourth-quarter acquired in-process research and development (IPR&D) expenses will help clarify the earnings outlook heading into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations